OMEPRAZOLE+CINITAPRIDE is used to treat gastroesophageal reflux disease (GERD), peptic ulcers and Zollinger-Ellison syndrome. Gastroesophageal reflux disease (GERD) occurs when stomach acid frequently flows back into the food pipe (oesophagus). Peptic ulcers are sores that develop on the inner lining of the intestine and stomach. Zollinger-Ellison syndrome is characterised by the formation of tumours in the upper part of the small intestine, which leads to excess acid production. OMEPRAZOLE+CINITAPRIDE is a combination of two drugs: Omeprazole (proton pump inhibitor) and Cinitapride (gastroprokinetic agent). Omeprazole works by blocking the action of proton pumps that produce stomach acid. It reduces the amount of acid the stomach produces and prevents excess acid from flowing back into the food pipe. On the other hand, Cinitapride increases the movement of the food pipe (oesophagus), small intestine and stomach, thereby enhancing bowel movement and the digestive tract empties from the food in a shorter time. Together, OMEPRAZOLE+CINITAPRIDE helps prevent acid reflux, thereby relieving hyperacidity and heartburn.